The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Abernethy Matt since 2018.
This trader's CIK number is 1724097.
At the time of last reporting, Abernethy Matt was the Chief Financial Officer of Neurocrine Biosciences Inc. (stock ticker symbol NBIX).
Also see all insider trading activities at Neurocrine Biosciences Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | NBIX | 0 | $0 | 3,538 | $414,833 | 6,667 | $0 |
| 2024 | NBIX | 0 | $0 | 49,895 | $7,067,497 | 45,000 | $3,311,999 |
| 2023 | NBIX | 0 | $0 | 32,003 | $3,302,967 | 0 | $0 |
| 2022 | NBIX | 0 | $0 | 4,290 | $345,475 | 0 | $0 |
| 2021 | NBIX | 0 | $0 | 4,555 | $475,818 | 0 | $0 |
| 2020 | NBIX | 0 | $0 | 26,864 | $2,862,727 | 15,000 | $1,104,000 |
| 2019 | NBIX | 0 | $0 | 1,645 | $191,361 | 0 | $0 |
| 2018 | NBIX | 0 | $0 | 1,178 | $106,020 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-02-13 | NBIX | Option Ex | 4,807 | .00 | 0 |
| 2025-02-13 | NBIX | Sale | 2,558 | 116.86 | 298,925 |
| 2025-02-08 | NBIX | Option Ex | 1,860 | .00 | 0 |
| 2025-02-10 | NBIX | Sale | 980 | 118.27 | 115,908 |
| 2024-08-13 | NBIX | Sale | 14,100 | 150.38 | 2,120,343 |
| 2024-08-13 | NBIX | Option Ex | 14,100 | 73.60 | 1,037,759 |
| 2024-07-16 | NBIX | Option Ex | 900 | 73.60 | 66,240 |
| 2024-07-16 | NBIX | Sale | 900 | 150.04 | 135,036 |
| 2024-05-15 | NBIX | Option Ex | 15,000 | 73.60 | 1,104,000 |
| 2024-05-14 | NBIX | Option Ex | 15,000 | 73.60 | 1,104,000 |
| 2024-05-15 | NBIX | Sale | 15,000 | 140.24 | 2,103,615 |
| 2024-05-14 | NBIX | Sale | 15,000 | 135.66 | 2,034,825 |
| 2024-02-13 | NBIX | Sale | 1,352 | 132.85 | 179,611 |
| 2024-02-06 | NBIX | Sale | 1,280 | 142.19 | 182,000 |
| 2024-02-08 | NBIX | Sale | 980 | 134.21 | 131,529 |
| 2024-01-31 | NBIX | Sale | 1,283 | 140.72 | 180,538 |
| 2023-08-21 | NBIX | Sale | 2,132 | 107.39 | 228,957 |
| 2023-02-07 | NBIX | Sale | 26,328 | 102.38 | 2,695,539 |
| 2023-02-08 | NBIX | Sale | 980 | 104.19 | 102,110 |
| 2023-02-06 | NBIX | Sale | 1,280 | 105.67 | 135,253 |
| 2023-01-31 | NBIX | Sale | 1,283 | 109.98 | 141,108 |
| 2022-02-07 | NBIX | Sale | 3,310 | 80.79 | 267,418 |
| 2022-02-08 | NBIX | Sale | 980 | 79.65 | 78,057 |
| 2021-12-01 | NBIX | Sale | 1,645 | 82.58 | 135,852 |
| 2021-02-08 | NBIX | Sale | 2,910 | 116.83 | 339,966 |
| 2020-12-01 | NBIX | Sale | 1,645 | 94.66 | 155,720 |
| 2020-11-12 | NBIX | Sale | 2,257 | 90.74 | 204,809 |
| 2020-08-05 | NBIX | Sale | 2,257 | 118.90 | 268,355 |
| 2020-05-07 | NBIX | Option Ex | 15,000 | 73.60 | 1,104,000 |
| 2020-05-07 | NBIX | Sale | 15,000 | 110.21 | 1,653,135 |
| 2020-04-28 | NBIX | Sale | 1,741 | 102.49 | 178,435 |
| 2020-04-24 | NBIX | Sale | 1,934 | 99.52 | 192,467 |
| 2020-02-07 | NBIX | Sale | 2,030 | 103.35 | 209,806 |
| 2019-12-02 | NBIX | Sale | 1,645 | 116.33 | 191,361 |
| 2018-12-03 | NBIX | Sale | 1,178 | 90.00 | 106,020 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Abernethy Matt (Chief Financial Officer of Neurocrine Biosciences Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.